首荟通便胶囊治疗2型糖尿病患者口服阿卡波糖后腹胀的有效性及安全性OA

Objective To explore the efficacy and safety of Shouhui Tongbei capsule in the treatment of abdominal distension after oral acarbose in patients with type 2 diabetes.Methods Forty-eight patients with type 2 diabetes with abdominal distension after oral acarbose treated in Cangzhou Central Hospital from January to December 2021 were selected as the study objects,and were divided into control group and observation group according to random number table method,with 24 cases in each group.The control group was given life intervention,and the observation group was given Shouhui Tongqi capsule on the basis of the control group.The therapeutic effect of the two groups was compared.Results The effective rate of treatment in the observation group was higher than that in the control group,the onset time and disappearance time of abdominal distension were shorter than that in the control group,and the fasting blood glucose level after treatment was lower than that in the control group,the difference was statistically significant(P＜0.05).After treatment,the scores of constipation symptoms and serum vasoactive intestinal peptide(VIP)levels in the two groups were decreased,and the observation group was lower,and the serum motilin(MTL)and serum Substance P(SP)levels in the two groups were increased,and the observation group was higher,the difference was statistically significant(P＜0.05).Conclusion Shouhuitongbei capsule has a good clinical effect on abdominal distention in type 2 diabetes patients after oral acarbose,which can shorten the time of drug onset and disappearance of abdominal distention,reduce fasting blood glucose level,regulate gastrointestinal hormone level,and no serious adverse reactions.